Profil
Martin Bott served as the VP-Corporate Finance & Investment Banking at Eli Lilly & Co. from 2015 to 2017.
He also served as an Independent Director at InMed Pharmaceuticals, Inc. from 2017 to 2019 and as a Director at CoLucid Pharmaceuticals, Inc. Additionally, he received an undergraduate degree from Universität zu Köln in 1985 and a graduate degree from the University of South Carolina in 1988.
Anciens postes connus de Martin Bott
| Sociétés | Poste | Fin |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Director/Board Member | 31/08/2019 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/12/2017 |
| COLUCID PHARMACEUTICALS INC | Director/Board Member | - |
Formation de Martin Bott
| Universität zu Köln | Undergraduate Degree |
| University of South Carolina | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| INMED PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
